Syngene concludes acquisition of biologics manufacturing facility from Emergent BioSolutions

The new site will increase Syngene's total single-use bioreactor capacity to 50,000L

Indegene launches new center in London

Financial Times names Indegene among high-growth companies in Asia-Pacific 2025

Indegene combines deep healthcare expertise with a digital-first approach to help pharma, biotech and medical device companies commercialize their products

Alkem launches generic empagliflozin and its combinations in India under ‘Empanorm’

Empagliflozin is used in the treatment of type-2 diabetes mellitus, chronic kidney disease and heart failure

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million

Indegene launches AI platform Cortex

This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain

Briefs: Syngene International and Cipla

Cipla Limited has received final approval from the USFDA for the New Drug Application submitted for ‘Nilotinib Capsules 50, 150 and 200 mg’

Peter Bains to replace Jonathan Hunt as CEO of Syngene

Peter Bains has over three decades of experience in the biotech and pharmaceutical industry

Syngene reports 18% jump in Q3 FY25 PAT at Rs. 131 Cr

Reported revenue from operations up by 11% to Rs. 944 crores Reported PAT (after exceptional items) up by 18% to Rs. 131 crore

Indegene wins 2025 BIG Innovation Award for Hyper-automated AI solution

Hyper-automated AI is a unified framework combining AI, ML, RPA, and NLQ to streamline data extraction, quality management, transformation, and actionable insights - all on a single platform